Gross Margin: 38.53%
Is the gross margin high or low?
The gross margin of 38.53% is in line with its 5-year average of 41.04%, near the low end of its 5-year range (38.53%–54.30%).
As of Monday, June 29, 2026. 9.68% below its 12-month average of 42.66%.
GEHC Gross Margin
Reported quarterly gross margin; no daily interpolation.
GEHC Average Gross Margin Chart
GEHC Current vs Average Gross Margin Chart
GEHC Gross Margin Metrics
GROSS MARGIN
38.53%
GROSS MARGIN AVG TTM
42.66%
GROSS MARGIN AVG 3Y
40.64%
GROSS MARGIN AVG 5Y
40.37%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-9.68%
CURRENT VS 3Y AVG
-5.19%
CURRENT VS 5Y AVG
-4.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 38.53% | 42.66% | 40.64% | 40.37% |
| ResMed Inc. (RMD)vs › | $29.05B | 61.69% | 58.02% | 57.09% | 57.33% |
| Zoetis Inc. (ZTS)vs › | $31.88B | 70.75% | 69.79% | 68.91% | 68.46% |
| Biogen Inc. (BIIB)vs › | $31.89B | 69.77% | 73.30% | 74.61% | 77.63% |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 26.11% | 30.59% | 32.75% | 33.07% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 74.95% | 75.03% | 73.28% | 73.00% |
| Centene Corp. (CNC)vs › | $32.44B | 14.93% | 11.28% | 11.33% | 11.71% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 61.84% | 60.23% | 62.09% | 63.91% |
| Medline Inc. (MDLN)vs › | $32.87B | 24.04% | 25.55% | 23.71% | 23.71% |
| Moderna, Inc. (MRNA)vs › | $26.69B | 55.35% | 54.80% | 53.09% | 65.45% |
Gross Margin Analysis
Gross Margin
38.5%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for GE HealthCare Technologies Inc. (GEHC)?
- The gross margin for GEHC stock is 38.53%.
- Is GE HealthCare Technologies Inc.'s gross margin high or low?
- The gross margin of 38.53% is in line with its 5-year average of 41.04%, near the low end of its 5-year range (38.53%–54.30%).
- What is the TTM average gross margin for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average gross margin for GEHC stock is 42.66%.
- What is the 3Y average gross margin for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average gross margin for GEHC stock is 40.64%.
- What is the 5Y average gross margin for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average gross margin for GEHC stock is 40.37%.
GEHC Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 38.53% |
| 2025-12-31 | 54.30% |
| 2025-09-30 | 38.69% |
| 2025-06-30 | 39.65% |
| 2025-03-31 | 42.12% |
| 2024-12-31 | 42.77% |
| 2024-09-30 | 41.66% |
| 2024-06-30 | 41.37% |
| 2024-03-31 | 40.90% |
| 2023-12-31 | 41.41% |
| 2023-09-30 | 40.13% |
| 2023-06-30 | 40.27% |
| 2023-03-31 | 40.17% |
| 2022-12-31 | 39.13% |
| 2022-09-30 | 38.75% |
| 2022-06-30 | 40.05% |
| 2022-03-31 | 38.64% |
| 2021-12-31 | 40.58% |
| 2021-09-30 | 41.05% |
| 2021-06-30 | 40.80% |
| 2021-03-31 | 40.80% |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini